MariaBaerMD

Oncology • Baltimore, MD

Professor of Hematology & Oncology, University MD School of Medicine

Join to view full profile

Dr. Baer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Baer's full profile

Already have an account?

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-8708

Fax+1 410-328-6896
Is this information wrong?

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
Vanderbilt University Medical CenterResidency, Internal Medicine, 1979 - 1982
Johns Hopkins University School of MedicineClass of 1979

Certifications & Licensure

MD State Medical License 2007 - 2024
NY State Medical License 1985 - 2008
TN State Medical License 1984 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 1998 Jan 01
Completed
Phase 3
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Start of enrollment: 1999 Nov 01
Completed
Phase 1
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Start of enrollment: 2004 Apr 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia Start of enrollment: 2006 Oct 01
Active, not recruiting
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720 Start of enrollment: 1997 Mar 15
Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Active, not recruiting
Phase 2
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
Active, not recruiting
Phase 1, Phase 2
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Start of enrollment: 2018 Oct 04
Active, not recruiting
Phase 3
Roles: Principal Investigator
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Oct 23
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Gabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, James Childress, Tahreem Iqbal, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Jen...> ;Leukemia Research. 2024 Mar 1
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee, J., Chatterjee, A., Scarpa, M., Bailey, C., Singh, P., Mustafa Ali, M., Kapoor, S., Wang, Y., Silvestri, G., Niyongere, S., Baer, M.> ;Cancer Research Communications. 2024 Feb 16
2 citations
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Zhang, Y., Kallen, M., Ning, Y., Emadi, A., Baer, M.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
2 citations
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
4 citations
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti A Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R ...> ;Blood Advances. 2023 Jun 13
1 citations
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Manish R Patel, William Donnellan, Michael Byrne, Adam S Asch, Amer M Zeidan, Maria R Baer, Amir T Fathi, Andrew T Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Ci...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
1 citations
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.
Vijaya Raj Bhatt, Angela M Ulrich, Geoffrey L Uy, Richard M Stone, Wendy Stock, Michael O Ojelabi, Jun Yin, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Maria R Baer, Sel...> ;JCO Oncology Practice. 2023 Jun 1
14 citations
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
Krzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, Deedra Nicolet, Andrew J Carroll, Kellie J Archer, Alice S Mims, Karilyn T Larkin, Shelley Orwick, Christopher ...> ;Leukemia. 2023 Apr 1
1 citations
Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia.
Mary Gudipati, Melody Butler, Rima Koka, Maria R Baer, Yi Ning> ;Genes. 2023 Feb 3
5 citations
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
17 citations
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D Cassaday, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kr...> ;Journal of Hematology & Oncology. 2022 Dec 10
36 citations
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J Schiller, Shira N Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S Wang, Karen P Seiter, And...> ;The Lancet. Haematology. 2023 Jan 1
4 citations
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H Duong, Patricia Kropf, Jakob Werner Hansen, Denice Tsao-Wei, Hyo Sik Jang, Ashkan Emadi, S...> ;Clinical Cancer Research. 2022 Dec 15
1 citations
Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype andR132C mutation.
Hanan Alkhaldi, Danielle Sewell, Yi Ning, Michael E Kallen, Ashkan Emadi, Nancy M Hardy, Maria R Baer> ;Leukemia & Lymphoma. 2022 Dec 1
8 citations
Activating STING1-dependent immune signaling inmutant and wild-type acute myeloid leukemia.
Aksinija A Kogan, Michael J Topper, Anna J Dellomo, Lora Stojanovic, Lena J McLaughlin, T Michael Creed, Christian L Eberly, Tami J Kingsbury, Maria R Baer, Michael D ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2022 Jul 5
3 citations
Impact of-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.
Elizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, Kathryn A F Kline, Danielle Sewell, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Maria R Baer...> ;Biology. 2022 Jun 15
29 citations
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphobla...
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, Brent L Wood, Min Fang, Matthew J Wieduwilt, Ibrahim Aldoss, Jae H Park, Rebecca B Klisovic, Maria R Baer, Wendy Stoc...> ;Journal of Clinical Oncology. 2022 May 10
Gastrointestinal Vasoocclusive Crisis in a Woman with Hemoglobin SC Disease.
Jean M Clement, Andrew Y Li, Brian W Berg, Jennie Y Law, Maria R Baer> ;The American Journal of Medicine. 2022 May 1
15 citations
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, Tian Mi, Rena G Lapidus, Vu H Duong, Ashkan Emadi, Sandrine Niyongere, Casey L O'Connell, Benjamin A Youngblood, Steph...> ;Clinical Cancer Research. 2022 Apr 1
7 citations
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Moaath K Mustafa Ali, Elizabeth M Corley, Hanan Alharthy, Kathryn A F Kline, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Ashkan Emadi, Maria R Baer> ;Frontiers in Oncology. 2022 Jan 1
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Michael E Kallen, Rima Koka, Zeba N Singh, Yi Ning, Mehmet H Kocoglu, Ashraf Z Badros, Sandrine Niyongere, Vu H Duong, Ashkan Emadi, Maria R Baer> ;Leukemia Research Reports. 2022 Jan 1
5 citations
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers.
Anna J. Dellomo, Rachel Abbotts, Christian Eberly, Mariusz Karbowski, Maria R. Baer, Tami J. Kingsbury, Feyruz V. Rassool> ;Translational Oncology. 2022 Jan 1
Join now to see all

Abstracts/Posters

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP In...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Association of Time to Initial Emergency Department Analgesia with Rate of Admission in Patients with Uncomplicated Sickle Cell Disease Vaso-Occlusive Crises
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

New Drug Combination Targets Aggressive Blood CancerMarch 7th, 2017
Researchers Identify Novel Mechanism in Combination Drug Therapy for Acute Myeloid Leukemia, Other CancersOctober 11th, 2016